Description du projet
Améliorer le traitement de l’insuffisance cardiaque aiguë
L’insuffisance cardiaque chronique est un problème médical important qui peut conduire à l’insuffisance cardiaque aiguë (ICA), la cause la plus fréquente d’hospitalisation chez les personnes âgées de plus de 65 ans. Le traitement standard de l’ICA implique l’administration de diurétiques pour faciliter la décongestion des fluides. Cependant, une proportion significative de patients atteints d’ICA a développé une résistance aux diurétiques. Le nombre de cas d’ICA étant appelé à augmenter du fait du vieillissement de la population, le projet Doraya, financé par l’UE, a mis au point un dispositif de cathéter innovant comme alternative au traitement diurétique, offrant une solution optimale pour restaurer la fonction des organes.
Objectif
Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure, which typically includes
difficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting millions of people around the
world (present in 1%-12% in Europe and the United States. The lifetime risk of developing the disease ranging in between
20%-33%). AHF is the most common cause of hospitalization for patients older than 65 years of age. Over the last 3
decades, the hospitalization rates for patients with AHF has tripled and is expected to increase. An ageing population will
increase the prevalence of AHF, which in turn will lead to significant monetary expenses. Fluid decongestion is the key
treatment of AHF, where 90% of patients are treated with diuretics. However, 30%-40% of patients are resistant to diuretics.
The DorayaTM is the first device to directly create an optimal hemodynamic environment, enabling diuretic efficiency to
relieve congestion and restore organ function. The DorayaTM catheter regulates vascular hemodynamics in AHF patients,
including those who have developed diuretic resistance. Chronic Heart Failure market is expected to increase from €2.64bn
in 2015 to €8.78bn in 2025, which represents a 12.9% of CAGR. Since, AHF market accounts for 75% of the total Chronic
Heart Failure market, the total available global market by 2025 is expected to reach €6.59bn. With 30% of patients resistant
to diuretics, this represents a huge unmet market that Doraya can service.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
4250407 NETANIA
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.